AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

Core Insights - AbbVie has entered a voluntary agreement with the Trump administration to enhance access and affordability of medications for Americans while fostering U.S. pharmaceutical innovation [1][3] Group 1: Financial Commitments - AbbVie will invest $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade [2][6] - The agreement allows AbbVie to provide low prices in Medicaid and expand direct-to-patient offerings through TrumpRx for widely used medications [2][6] Group 2: Strategic Goals - AbbVie aims to address the complexities and access challenges in the U.S. healthcare system, serving approximately 16 million Americans annually with its products [3] - The agreement aligns with President Trump's drug pricing priorities and includes exemptions from tariffs and future price mandates [3][6] Group 3: Company Mission - AbbVie's mission focuses on discovering and delivering innovative medicines that address serious health issues and future medical challenges across key therapeutic areas [4]